Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-06-30
2010-06-15
Eyler, Yvonne L (Department: 1619)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S262100, C514S649000, C514S283000, C514S449000, C514S309000
Reexamination Certificate
active
07737147
ABSTRACT:
Methods for treatment of sexual dysfunction in men and women using combinations of phosphodiesterase (PDE) type 5 inhibitors and l-deprenyl or propargylamine compounds are described. Methods of reducing the dosage and preventing the side effects of PDE type 5 inhibitors are also described. The methods comprise administering a therapeutically effective amount of l-deprenyl or propargylamine compounds (also called monoamine oxidase [MAO] inhibitors) in combination with PDE inhibitors. Stimulation of nitric oxide production and vasodilation by l-deprenyl and propargylamine compounds augments the actions of PDE inhibitors or other drugs and methods used in the treatment of sexual dysfunction. The composition described here enhances the actions of PDE inhibitors primarily by increasing the generation of cyclic GMP by stimulating the nitric oxide pathway and secondarily by providing several additional benefits such as enhanced dopamine activity. Methods of enhancing the efficacy of various PDE inhibitors in the treatment of a number of disorders other than sexual dysfunction are also disclosed.
REFERENCES:
patent: 5658936 (1997-08-01), Kifor et al.
patent: 6338862 (2002-01-01), Niazi
patent: 6395744 (2002-05-01), Adams
patent: 6403597 (2002-06-01), Wilson
patent: 6432991 (2002-08-01), Thomas
patent: 6476037 (2002-11-01), Wallace
patent: 6548490 (2003-04-01), Doherty, Jr.
patent: 6635667 (2003-10-01), Thomas
Thomas, T. (2000) Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging. 21: 343-348.
Thomas, T (2001) A role for estrogen in the primary prevention of Alzheimer's disease. Climacteric. 4: 102-109.
Thomas,T, et al. (2002) Inhibition of LDL oxidation by the neuroprotective drug I-deprenyl. Neurol. Res. 24: 169-173.
Thomas, T. et al. (1998) L-deprenyl: nitric oxide production and dilation of cerebral blood vessels. NeuroReport. 9: 1-6.
Thomas, T. et al. (1998) L-deprenyl protects vascular endothelium from amyloid-beta toxicity and stimulates production of nitric oxide. In Alzheimer's disease and related disorders. (Ed. Iqbal K. et al.) pp. 493-500, John Wiley and Sons Ltd.
Maas, R. et al (2003) The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vascular Medicine 7: 213-225.
Galle G. and Trummer, H. (2003). The etiology of erectile dysfunction and mechanisms by which drugs improve erection. Drugs of Today, 39: 193-201.
Gonzalez-Cadavid, NF. and Rajfer, J. (2000) Therapeutic stimulation of penile nitric oxide synthase and related pathways. Drugs of Today. 36: 163-174.
Tomlinson J. and Wright D. (2004) Impact of erectile dysfunction and its treatment with Sildenafil: qualitative study. Brit. Med. J. 328: 1037.
Eyler Yvonne L
Jagoe Donna
Smith & Hopen , P.A.
Varkonyi Robert
LandOfFree
Methods and compositions to enhance the efficacy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions to enhance the efficacy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions to enhance the efficacy of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199710